Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-8877-3600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.02 million
Profitability
Miscellaneous
Employees149
Next Earnings Date5/15/2019 (Estimated)
OptionableNot Optionable
ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions
What is ZEALAND PHARMA/S's stock symbol?
ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."
When is ZEALAND PHARMA/S's next earnings date?
What price target have analysts set for ZEAL?
3 equities research analysts have issued 12 month price objectives for ZEALAND PHARMA/S's stock. Their predictions range from $29.00 to $29.00. On average, they anticipate ZEALAND PHARMA/S's share price to reach $29.00 in the next year. This suggests a possible upside of 67.2% from the stock's current price. View Analyst Price Targets for ZEALAND PHARMA/S.
What is the consensus analysts' recommendation for ZEALAND PHARMA/S?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZEALAND PHARMA/S.
What are Wall Street analysts saying about ZEALAND PHARMA/S stock?
Here are some recent quotes from research analysts about ZEALAND PHARMA/S stock:
- 1. Needham & Company LLC analysts commented, "Zealand mgmt hosted a 4Q18 conference call today to provide a corporate update." (3/7/2019)
- 2. According to Zacks Investment Research, "Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. " (1/1/2019)
Has ZEALAND PHARMA/S been receiving favorable news coverage?
Media coverage about ZEAL stock has trended somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of ZEALAND PHARMA/S's key competitors?
Some companies that are related to ZEALAND PHARMA/S include PTC Therapeutics (PTCT), Myokardia (MYOK), Insmed (INSM), Arena Pharmaceuticals (ARNA), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Nabriva Therapeutics (NBRV), Madrigal Pharmaceuticals (MDGL), Endocyte (ECYT), The Medicines (MDCO), AnaptysBio (ANAB), Endo International (ENDP), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX) and Enanta Pharmaceuticals (ENTA).
What other stocks do shareholders of ZEALAND PHARMA/S own?
Who are ZEALAND PHARMA/S's key executives?
ZEALAND PHARMA/S's management team includes the folowing people:
- Mr. Mats Peter Blom M.B.A., MBA, Exec. VP & CFO (Age 54)
- Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 66)
- Mr. Adam Steensberg M.D., Interim CEO, Exec. VP and Chief Medical & Devel. Officer (Age 45)
- Thierry Lanuque, Head of Fin. & Accountant
- Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 54)
When did ZEALAND PHARMA/S IPO?
(ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.
Who are ZEALAND PHARMA/S's major shareholders?
ZEALAND PHARMA/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Jane Street Group LLC (0.08%), United Services Automobile Association (0.07%) and OLD Mission Capital LLC (0.06%).
Which institutional investors are selling ZEALAND PHARMA/S stock?
ZEAL stock was sold by a variety of institutional investors in the last quarter, including United Services Automobile Association.
Which institutional investors are buying ZEALAND PHARMA/S stock?
ZEAL stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC and OLD Mission Capital LLC.
How do I buy shares of ZEALAND PHARMA/S?
Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZEALAND PHARMA/S's stock price today?
One share of ZEAL stock can currently be purchased for approximately $17.34.
How big of a company is ZEALAND PHARMA/S?
ZEALAND PHARMA/S has a market capitalization of $533.38 million and generates $6.02 million in revenue each year. The company earns $92.07 million in net income (profit) each year or $3.00 on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe.
What is ZEALAND PHARMA/S's official website?
How can I contact ZEALAND PHARMA/S?
ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]
MarketBeat Community Rating for ZEALAND PHARMA/S (NASDAQ ZEAL)
MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
